Note Year ended Dec 2024 $’000 Year ended Dec 2023 $’000 Cash flows from operating activities Receipts from licence agreement 51,421 221,004 Income tax paid (37,221) – Withholding tax paid (2,517) (11,840) Receipts from Australian R&D Tax Incentive – 882 Interest received 11,297 4,360 GST refunded 353 272 Payments for employees and directors (4,145) (5,161) Payments to other suppliers (30,458) (24,592) Net cash (used in)/from operating activities 5 (11,270) 184,925 Cash flows from investing activities Purchase of plant and equipment (10) (40) Less cash transferred from/(to) short-term investments(i) 4,144 (211,445) Net cash from/(used in) investing activities 4,134 (211,485) Cash flows from financing activities Proceeds from issue of shares 16 1,660 3,637 Payment of share issue expenses 16 (9) (18) Payments for share buy-back 16 (10,426) – Net cash (used in)/from financing activities (8,775) 3,619 Net decrease in cash and cash equivalents (15,911) (22,941) Cash and cash equivalents at the beginning of the financial year 17,094 40,180 Effects of exchange rate changes on cash and cash equivalents 1,970 (145) Cash and cash equivalents at the end of the financial year 10 3,153 17,094 (i) Following the receipt of the first commercial sale milestone payment from Acadia, the Company is holding more funds than are required to meet currently forecast short-term cash commitments. As a result, the Company has reclassified cash held in short-term deposits from Cash and Cash Equivalents to Shortterm Investments. CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2024 The above consolidated statement of cash flows should be read in conjunction with the accompanying notes Neuren Pharmaceuticals Limited Annual Report 2024 27
RkJQdWJsaXNoZXIy MjE2NDg3